Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VA-MENGOC-BC
- Development stage
- Unknown
- Lead developer
- Finlay Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VA-MENGOC-BC is a bivalent vaccine designed to provide active immunity against meningococcal disease caused by *Neisseria meningitidis* serogroups B and C. Developed by the Finlay Institute in Cuba and manufactured in Vietnam by Vabiotech, the vaccine consists of the outer membrane protein (OMP) complex from *N. meningitidis* serogroup B (specifically the B:4:P1.19,15 strain) and the purified capsular polysaccharide of *N. meningitidis* serogroup C. The antigens are adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. It is administered via intramuscular injection and is primarily used for the prevention of meningitis and sepsis in infants, children, and adults.
- Brand names
- VA-MENGOC-BC
- Other names
- VAMENGOC-BCMeningococcal BC vaccine
02
Targets
Neisseria meningitidis serogroup B outer membrane antigensTLR9 (Toll-like receptor 9)Neisseria meningitidis serogroup B lipooligosaccharide within outer membrane vesiclesTLR4 (Toll-like receptor 4)H.8 (Neisseria gonorrhoeae homologous outer membrane protein)Neisseria meningitidis group C capsular polysaccharideTLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on VA-MENGOC-BC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VA-MENGOC-BC.